Author

C. Arora

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B077: FOLFIRINOX Bolsters the Intratumoral and Systemic B Cell Activation Compared to Gemcitabine-Abraxane in Patients with PDAC

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer related deaths in the world, and its poor prognosis is driven by an immunosuppressive tumor microenvironment (TME). Standard PDAC treatment combines surgical resection with perioperative chemotherapy, either Gemcitabine-Abraxane (Gem) or FOL...

C. Arora, Renee R. Anderko, Adam Tcharni et al. · Cancer Research · 0 citations

Sep 2026

Abstract B115: Divergent T cell exhaustion dynamics in periphery versus tumor during neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a five-year survival rate of 13%. Neoadjuvant therapy (NAT) is thought to reshape anti-tumor immunity, but its effects on circulating T cell composition/exhaustion and how this relates to intratum...

Umayal Sivagnanalingam, Renee R. Anderko, C. Arora et al. · Cancer Research · 0 citations

Sep 2026

Abstract A018: Cancer Associated Fibroblasts regulate Humoral Immunity and B Cell Education within Tertiary Lymphoid Structures

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of just 13%. Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet has shown limited efficacy in PDAC, benefiting fewer than 1% of patients to date. Contributing to this, the PDAC tumor microenvironment (TME) is desmoplastic and comp...

Braden T. Stevenson, C. Arora, Maya Sivagnanalingam et al. · Cancer Research · 0 citations